Showing results (1-10 of 66) with videos related to
Sort By:
Pageof 7
Current Opinion in HIV and AIDS|April 18, 2009
Treatment interruption in advanced failing patientsSchlomo StaszewskiAntiviral Therapy|August 24, 2007
Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIVMartin Stürmer, Schlomo Staszewski, Hans Wilhelm DoerrJournal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 7, 2002
Evaluation of the LiPA HIV-1 RT assay version 1: comparison of sequence and hybridization based genotyping systemsMartin Stürmer, Birgit Morgenstern, Schlomo Staszewski, et al.AIDS Research and Human Retroviruses|December 18, 2003
A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failureMartin Stürmer, Schlomo Staszewski, Hans W Doerr, et al.Antiviral Therapy|August 20, 2003
Comparison of nine resistance interpretation systems for HIV-1 genotypingMartin Stürmer, Hans Wilhelm Doerr, Schlomo Staszewski, et al.AIDS (London, England)|September 10, 2003
Definition of loss of virological response in trials of antiretroviral drugsSchlomo Staszewski, Caroline Sabin, Brenda Dauer, et al.HIV Clinical Trials|October 30, 2003
Patient acceptance of self-injected enfuvirtide at 8 and 24 weeksCalvin Cohen, James Hellinger, Margaret Johnson, et al.Antimicrobial Agents and Chemotherapy|December 25, 2002
Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214Martin Stürmer, Schlomo Staszewski, Hans-Wilhelm Doerr, et al.Scandinavian Journal of Infectious Diseases|July 14, 2005
Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosisMarkus Bickel, Christoph Stephan, Carsten Rottmann, et al.Antiviral Therapy|February 5, 2008
Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patientsNils von Hentig, Errol Babacan, Schlomo Staszewski, et al.Pageof 7